PRA Health Sciences (PRAH) Given a $94.00 Price Target at Robert W. Baird

PRA Health Sciences (NASDAQ:PRAH) has been assigned a $94.00 price objective by equities research analysts at Robert W. Baird in a report issued on Friday. The brokerage currently has a “buy” rating on the medical research company’s stock. Robert W. Baird’s price objective would suggest a potential upside of 14.84% from the company’s current price.

PRAH has been the topic of several other research reports. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Friday, September 15th. SunTrust Banks reaffirmed a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. KeyCorp reaffirmed a “buy” rating and issued a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Citigroup reaffirmed a “buy” rating and issued a $93.00 price target (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Mizuho set a $87.00 price target on PRA Health Sciences and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $89.09.

PRA Health Sciences (PRAH) opened at $81.85 on Friday. PRA Health Sciences has a 12 month low of $51.16 and a 12 month high of $84.38. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $5,219.77, a PE ratio of 30.28, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. During the same quarter last year, the company earned $0.64 EPS. The firm’s revenue was up 23.7% compared to the same quarter last year. equities analysts expect that PRA Health Sciences will post 3.2 earnings per share for the current year.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of PRA Health Sciences by 28.2% during the 2nd quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock valued at $274,759,000 after buying an additional 805,573 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of PRA Health Sciences by 318.3% during the 2nd quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after buying an additional 1,655,336 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of PRA Health Sciences by 55.8% during the 3rd quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after buying an additional 432,449 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of PRA Health Sciences by 3.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 915,111 shares of the medical research company’s stock valued at $69,704,000 after buying an additional 29,771 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of PRA Health Sciences by 5.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 834,034 shares of the medical research company’s stock valued at $63,528,000 after buying an additional 45,227 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “PRA Health Sciences (PRAH) Given a $94.00 Price Target at Robert W. Baird” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/pra-health-sciences-prah-receives-buy-rating-from-robert-w-baird.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply